SCHEMBL161723

SCHEMBL161723

C[C@@](N)(CC(N)=O)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GGT1 P19440 1/20 0.46
NOS2 P35228 5/20 0.43
ARG1 P05089 1/20 0.42
ARG2 P78540 1/20 0.42
BLM P54132 2/20 0.41
NOS1 P29475 3/20 0.40
TSHR P16473 2/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
HIF1A Q16665 1/20 0.40
NOS3 P29474 1/20 0.40
ALDH1A1 P00352 4/20 0.37
ADRA1A P35348 2/20 0.37
KDM4E B2RXH2 2/20 0.37
MEN1 O00255 2/20 0.37
CYP1A2 P05177 2/20 0.37
KMT2A Q03164 2/20 0.37
USP2 O75604 1/20 0.37
EGFR P00533 1/20 0.37
FYN P06241 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL161722 1.00 GGT1 (0.46) GGT1NOS2ARG1ARG2BLM
SCHEMBL573396 1.00 GGT1 (0.46) GGT1NOS2ARG1ARG2BLM
Asparagine SCHEMBL7046551 0.82 GRIK1 (0.42) GGT1BLMKMT2AALOX15PMP22
SCHEMBL28453562 0.81 FDPS (0.33) GGT1NOS2ARG1ARG2BLM
SCHEMBL9823655 0.81 FDPS (0.33) GGT1NOS2ARG1ARG2BLM
SCHEMBL28610049 0.81 FDPS (0.33) GGT1NOS2ARG1ARG2BLM
SCHEMBL1875520 0.81 TSHR (0.55) GGT1NOS2ARG1ARG2BLM
SCHEMBL162455 0.81 TSHR (0.55) GGT1NOS2ARG1ARG2BLM
SCHEMBL1660876 0.81 TSHR (0.55) GGT1NOS2ARG1ARG2BLM
SCHEMBL1986433 0.79 GGT1 (0.46) GGT1NOS2ARG1ARG2BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1802 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250296915-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2025-09-25 US claimed
US-20090215895-A1 Therapeutic and carrier molecules PEPLIN BIOLIPIDS PTY LTD (AU) 2009-08-27 US claimed
EP-1718602-A4 THERAPEUTIC AND CARRIER MOLECULES PEPLIN BIOLIPIDS PTY LTD (AU) 2007-12-12 EP claimed
US-7256172-B1 Method of treatment and agents useful for same THE UNIVERSITY OF MELBOURNE (AU) 2007-08-14 US claimed
EP-1718602-A1 THERAPEUTIC AND CARRIER MOLECULES Peplin Biolipids Pty Ltd. (AU) 2006-11-08 EP claimed
US-7070969-B1 Plasmin inhibitors from the australian brown snake Pseudonaja textilis textilis THE UNIVERSITY OF QUEENSLAND (AU) 2006-07-04 US claimed
WO-2005073164-A1 THERAPEUTIC AND CARRIER MOLECULES PEPLIN BIOLIPIDS PTY LTD (AU) 2005-08-11 WO claimed
WO-2026085582-A1 PROTEIN CAGES THE UNIVERSITY OF SYDNEY (AU) 2026-04-30 WO disclosed
EP-4627079-A2 THERMOSTABLE BINDING SCAFFOLDS Nectagen, Inc. (US) 2025-10-08 EP disclosed
US-20250296915-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2025-09-25 US disclosed
CN-120202191-A Inhibitors of prostate specific membrane antigen and uses thereof 上海先通生物科技有限公司 2025-06-24 CN disclosed
EP-4551563-A2 FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF CIDARA THERAPEUTICS, INC. (US) 2025-05-14 EP disclosed
WO-2025091087-A1 BISPECIFIC PROTEINS MONASH UNIVERSITY (AU) 2025-05-08 WO disclosed
WO-1997005257-A1 PEPTIDE ANALOG INHIBITORS OF UROKINASE RECEPTOR ACTIVITY CHIRON CORPORATION (US) 1997-02-13 WO disclosed
WO-1997004091-A1 NOVEL RECEPTOR LIGANDS AND GENETIC SEQUENCES ENCODING SAME AMRAD OPERATIONS PTY. LTD. (AU) 1997-02-06 WO disclosed
EP-0745092-A1 PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY CHIRON CORPORATION (US) 1996-12-04 EP disclosed
EP-0672049-A1 SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS CHIRON MIMOTOPES PTY. LTD. (AU) 1995-09-20 EP disclosed
WO-1994028014-A2 PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY CHIRON CORPORATION (US) 1994-12-08 WO disclosed
WO-1994011388-A1 SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS CHIRON MIMOTOPES PTY. LTD. (AU) 1994-05-26 WO disclosed
WO-1994003483-A1 ENDOTHELIN RECEPTOR-BINDING COMPOUNDS CHIRON CORPORATION (US) 1994-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215895-A1 Therapeutic and carrier molecules PHKG1, PHKG2, DGKB GGT1 1211/4885NOS2 704/4885ARG1 4434/4885
US-20250296915-A1 NOVEL AMINO ACID DERIVATIVES DNPEP, BCAT1, ANPEP GGT1 2048/4885NOS2 2347/4885ARG1 220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.